Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review

被引:3
|
作者
Sechi, Illari [1 ]
Muresu, Narcisa [2 ]
Di Lorenzo, Biagio [3 ]
Saderi, Laura [3 ]
Puci, Mariangela [3 ]
Aliberti, Stefano [4 ]
Maida, Ivana [1 ]
Mondoni, Michele [5 ]
Piana, Andrea [1 ]
Sotgiu, Giovanni [3 ]
机构
[1] Univ Sassari, Dept Med Surg & Pharm, I-07100 Sassari, Italy
[2] Univ Sassari, Dept Humanities & Social Sci, I-07100 Sassari, Italy
[3] Univ Sassari, Dept Med Surg & Expt Med, Clin Epidemiol & Med Stat Unit, I-07100 Sassari, Italy
[4] Humanitas Univ, Dept Biomed Sci, I-20072 Pieve Emanuele, Italy
[5] Univ Milan, Dept Hlth Sci, Resp Unit, ASST Santi Paolo & Carlo, I-20122 Milan, Italy
关键词
recurrent respiratory papillomatosis; HPV; lung cancer; lung involvement; pulmonary involvement; SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS; JUVENILE-ONSET; RISK-FACTORS; CLINICAL-COURSE; LUNG; TRANSFORMATION; INFECTION; DIAGNOSIS; CANCER;
D O I
10.3390/idr16020016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Recurrent respiratory papillomatosis (RRP) is a non-malignant disease, characterized by the production of wart-like growths in the respiratory tract, affecting both young people and adults (juvenile-onset recurrent respiratory papillomatosis, JORRP, and adult-onset recurrent respiratory papillomatosis, AORRP, respectively). Infection caused by human papillomavirus (HPV) is known as the main factor involved in RRP development. Complications of RRP may rarely occur, including lung involvement and malignant transformation. The present systematic review aimed to evaluate the prevalence of severe complications, such as lung involvement and lung tumor in JORRP and AORRP patients, and assess the role of HPV genotypes in the progression of disease severity following the guideline for reporting systematic reviews and meta-analysis (PRISMA Statement). A total of 378 studies were found on PubMed and Scopus using the following MESH terms: "recurrent respiratory papillomatosis and lung tumor" and "pulmonary tumor and recurrent respiratory papillomatosis". Basing on inclusion and exclusion criteria, a total of 11 studies were included in the systematic review. We found a pooled prevalence of 8% (95% CI: 4-14%; I2: 87.5%) for lung involvement in RRP patients. In addition, we found a pooled risk difference of 5% in lung involvement between JORRP and AORRP (95% CI: -7-18%; I2: 85.6%, p-value: 0.41). Among patients with lung involvement, we observed a pooled prevalence of lung tumor of 4% (95% CI:1-7%; I2: 67.1%) and a pooled prevalence mortality for this group of 4% (95% CI:2-6%; I2: 0%). Overall, the positivity rate for HPV-6 and -11 in patients with RRP was 91%. Considering only cases with pulmonary involvement, the pooled prevalence for HPV-11 was 21% (95% CI: 5-45%; I2: 77.2%). Our results evidenced a low/middle risk of pulmonary involvement and lung tumor in JORRP and AORRP patients, with an increased risk for HPV-11-positive patients. Further studies should be performed to improve knowledge and adopt preventive measures to contrast the progression to severe diseases in RRP patients.
引用
收藏
页码:200 / 215
页数:16
相关论文
共 50 条
  • [1] Recurrent respiratory papillomatosis with pulmonary involvement
    Ikawa, Marcos Hiroyuki
    Portes Meirelles, Gustavo Souza
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2008, 41 (01) : 89 - 90
  • [2] Recurrent respiratory papillomatosis with pulmonary involvement: A case report and review of the literature
    Ruan, Sheng-Yuan
    Chen, Kuan-Yu
    Yang, Pan-Chyr
    RESPIROLOGY, 2009, 14 (01) : 137 - 140
  • [3] Lung involvement in juvenile onset recurrent respiratory papillomatosis:: A systematic review of the literature
    Gelinas, Jean-Francois
    Manoukian, John
    Cote, Aurore
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2008, 72 (04) : 433 - 452
  • [4] Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement
    So, Raymond J. J.
    Lopez, Julio C. Hidalgo C.
    Ballestas, Samir A. A.
    Klein, Adam M. M.
    Steuer, Conor
    Shin, Dong M. M.
    Abousaud, Marin
    Teng, Yong
    Saba, Nabil F. F.
    Tkaczuk, Andrew T. T.
    Schaefer, Eric S. S.
    Seiwert, Tanguy Y. Y.
    McClellan, Kim
    Best, Simon R. R.
    LARYNGOSCOPE, 2024, 134 (02): : 577 - 581
  • [5] Recurrent respiratory papillomatosis with lung involvement
    Glikman, D
    Baroody, FM
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24): : E22 - E22
  • [6] Recurrent respiratory papillomatosis with lung involvement
    Aggunlu, Levent
    Erbas, Gonca
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2009, 15 (02) : 93 - 95
  • [7] Recurrent respiratory papillomatosis with esophageal involvement
    Batra, PS
    Herbert, RL
    Haines, GK
    Holinger, LD
    INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2001, 58 (03) : 233 - 238
  • [8] Recurrent respiratory papillomatosis with lung involvement
    Molodtsova, Valentina
    Ryabova, Marina
    Dvorakovskaya, Ivetta
    Vasilyeva, Marya
    Akopov, Andrey
    RESPIRATORY MEDICINE CASE REPORTS, 2018, 25 : 323 - 326
  • [9] Recurrent Respiratory Papillomatosis: A Review
    Derkay, Craig S.
    Wiatrak, Brian
    LARYNGOSCOPE, 2008, 118 (07): : 1236 - 1247
  • [10] Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review
    Pogoda, Louis
    Ziylan, Fuat
    Smeeing, Diederik P. J.
    Dikkers, Frederik G.
    Rinkel, Rico N. P. M.
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (09) : 4229 - 4240